Gelesis's Obesity Product FDA Acceptance Gives Boost To PureTech's Portfolio
You may also be interested in...
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Qiagen's therascreen FGFR RGQ RT-PCR companion diagnostic for Janssen's new drug to treat specific types of urothelial cancer and Intact Vascular's Tack device to treat dissections of the above-the-knee peripheral arteries following angioplasty.
Daphne Zohar tells Scrip PureTech will use $100m placing to develop Boston-based group's growth-stage affiliates and advance its "BIG" proprietary pipeline of brain-immune-gut assets.